IA
AKBA icon

IndexIQ Advisors’s Akebia Therapeutics AKBA Stock Holding History

IndexIQ Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-99,038
Closed -$626K – 1016
2019
Q4 		$626K Sell
99,038
-31,435
-24% -$149K 0.02% 412
2019
Q3 		$511K Sell
130,473
-24,440
-16% -$105K 0.02% 468
2019
Q2 		$750K Sell
154,913
-30,894
-17% -$176K 0.02% 448
2019
Q1 		$1.52M Buy
+185,807
New +$1.28M 0.04% 374

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

IndexIQ Advisors's AKBA Position: Q1 2020 in Review

IndexIQ Advisors sold out of Akebia Therapeutics (AKBA) in Q1 2020, closing a stake of 99,038 shares — an estimated $626K sold.

IndexIQ Advisors first reported a position in AKBA in Q1 2019 and held it in 4 quarters. The position peaked at $1.52M in Q1 2019. 155 funds tracked by Wall St. Rank hold AKBA as of Q1 2020.

  • IndexIQ Advisors reported no remaining Akebia Therapeutics position as of Q1 2020 after selling out during the quarter.
  • IndexIQ Advisors sold 99,038 Akebia Therapeutics shares in Q1 2020, an estimated $626K.
  • IndexIQ Advisors first reported a position in Akebia Therapeutics in Q1 2019 and held it in 4 quarters.
  • IndexIQ Advisors's Akebia Therapeutics position peaked at $1.52M in Q1 2019.
  • 155 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2020.

Based on IndexIQ Advisors's 13F filing for Q1 2020, filed 8 May 2020.